Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GNRHR | P30968 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20543509 | 0.91 | GAA (0.37) | RAB9AMAPTNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL20543611 | 0.90 | THRB (0.42) | THRBRAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL24027401 | 0.89 | PDE3B (0.35) | RAB9AMAPTNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL20543673 | 0.89 | THRB (0.39) | THRBRAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL30110604 | 0.89 | THRB (0.39) | THRBRAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL20543625 | 0.89 | GNRHR (0.40) | RAB9ANPC1ALDH1A1KMT2AGNRHR | |
| SCHEMBL20543506 | 0.86 | GAA (0.37) | RAB9AMAPTNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL20548364 | 0.86 | GAA (0.35) | RAB9AMAPTNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL21879026 | 0.86 | NPC1 (0.38) | RAB9AMAPTNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL25760294 | 0.85 | RAB9A (0.40) | THRBRAB9AMAPTNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3964501-B1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | PASTEUR INSTITUT (FR) | 2024-09-04 | — | — | EP | claimed |
| US-20240197923-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2024-06-20 | — | — | US | claimed |
| EP-3964501-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2022-03-09 | — | — | EP | claimed |
| US-20200129644-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2020-04-30 | — | — | US | claimed |
| EP-3615516-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | Institut Pasteur (FR) | 2020-03-04 | — | — | EP | claimed |
| WO-2018197727-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2018-11-01 | — | — | WO | claimed |
| EP-3395803-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | Institut Pasteur (FR) | 2018-10-31 | — | — | EP | claimed |
| US-12612411-B1 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2026-04-28 | — | — | US | disclosed |
| US-12576164-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2026-03-17 | — | — | US | disclosed |
| US-20240361321-A1 | LUMINESCENT BASED ANTIGEN ASSAY | INSTITUT PASTEUR (FR) | 2024-10-31 | — | — | US | disclosed |
| EP-3964501-B1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | PASTEUR INSTITUT (FR) | 2024-09-04 | — | — | EP | disclosed |
| EP-4392460-A1 | LUMINESCENT BASED ANTIGEN ASSAY | Institut Pasteur (FR) | 2024-07-03 | — | — | EP | disclosed |
| US-20240197923-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2024-06-20 | — | — | US | disclosed |
| EP-3615516-B1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | PASTEUR INSTITUT (FR) | 2021-11-17 | — | — | EP | disclosed |
| EP-3904508-A1 | LUCIFERASE LINKED IMMUNOSORBENT ASSAY | Institut Pasteur (FR) | 2021-11-03 | — | — | EP | disclosed |
| US-20200129644-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2020-04-30 | — | — | US | disclosed |
| US-20200129644-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2020-04-30 | — | — | US | disclosed |
| EP-3615516-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | Institut Pasteur (FR) | 2020-03-04 | — | — | EP | disclosed |
| WO-2018197727-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2018-11-01 | — | — | WO | disclosed |
| EP-3395803-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | Institut Pasteur (FR) | 2018-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129644-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | NISCH, HLCS, CYP3A5 | THRB 3921/4885RAB9A 4323/4885MAPT 4555/4885 |
| US-12576164-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | LUC7L2, HLCS, LANCL1 | THRB 2392/4885RAB9A 2680/4885MAPT 4875/4885 |
| US-12612411-B1 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | LUC7L2, MRPL21, CRY1 | THRB 710/4885RAB9A 3635/4885MAPT 4842/4885 |
| US-20240197923-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | NISCH, HLCS, CYP3A5 | THRB 3921/4885RAB9A 4323/4885MAPT 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.